Uploaded September 2018 | Updated November 2026, 3 hours ago
The U.S. is actively negotiating with Mexico and Canada to revise the North American Free Trade Agreement (NAFTA). Provisions under discussion would increase brand-name drug exclusivity (monopolies). Imposing additional brand-name drug exclusivity would keep already high brand drug prices out of reach for patients for longer.
Patients continue to pay skyrocketing brand drug prices as access to more affordable generics is delayed and the emerging biosimilars market in the U.S. is undermined.
Competition is a proven solution lower drug prices. When patients are able to access more-affordable generics and biosimilars, experience shows significant cost savings at the pharmacy counter.
However, far too often, trade agreements are used as an opportunity to export the policies that keep drug prices high in the U.S. to other countries. And a new NAFTA may be the latest attempt. Concern about the inclusion of additional brand-name drug exclusivity in NAFTA is widespread.
Learn more at: bit.ly/NewNAFTA
The U.S. is actively negotiating with Mexico and Canada to revise the North American Free Trade Agreement (NAFTA). Provisions under discussion would increase brand-name drug exclusivity (monopolies). Imposing additional brand-name drug exclusivity would keep already high brand drug prices out of reach for patients for longer.
Patients continue to pay skyrocketing brand drug prices as access to more affordable generics is delayed and the emerging biosimilars market in the U.S. is undermined.
Competition is a proven solution lower drug prices. When patients are able to access more-affordable generics and biosimilars, experience shows significant cost savings at the pharmacy counter.
However, far too often, trade agreements are used as an opportunity to export the policies that keep drug prices high in the U.S. to other countries. And a new NAFTA may be the latest attempt. Concern about the inclusion of additional brand-name drug exclusivity in NAFTA is widespread.
Learn more at: bit.ly/NewNAFTA










